by Portfolio Grader | August 29, 2012 12:30 pm
This week, 8 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
This week, Celgene (NASDAQ:CELG) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celgene is a global integrated biopharmaceutical company engaged in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. In Portfolio Grader’s specific subcategory of Equity, CELG also gets an A. For more information, get Portfolio Grader’s complete analysis of CELG stock.
Ariad Pharmaceuticals (NASDAQ:ARIA) is seeing ratings go up from a B last week to an A this week. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. Wall Street seems to agree with the upgrade and has propelled the stock up 7.6% over the past month. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Arena Pharmaceuticals (NASDAQ:ARNA) shows solid improvement this week. The company’s rating rises from a B to an A. Arena Pharmaceuticals is a clinical-stage biopharmaceutical company that develops innovative therapies offering medical advances and new options for patients. For more information, get Portfolio Grader’s complete analysis of ARNA stock.
Myriad Genetics (NASDAQ:MYGN) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Myriad Genetics develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage. For more information, get Portfolio Grader’s complete analysis of MYGN stock.
This week, China Biologic Products‘s (NASDAQ:CBPO) ratings are up from a C last week to a B. China Biologic Products is a biopharmaceutical company that engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers. For more information, get Portfolio Grader’s complete analysis of CBPO stock.
This week, Repligen Corp. (NASDAQ:RGEN) pushes up from a B to an A rating. Repligen is a biopharmaceutical company that develops therapeutics for radiology and neuropsychiatry. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 37.8% over the past month. For more information, get Portfolio Grader’s complete analysis of RGEN stock.
Astex Pharmaceuticals (NASDAQ:ASTX) improves from a C to a B rating this week. Astex Pharmaceuticals engages in the discovery and development of small molecule therapeutics with a focus on oncology and hematology. Wall Street has pushed the stock higher by 13.8% over the past month. For more information, get Portfolio Grader’s complete analysis of ASTX stock.
Nanosphere Inc. (NASDAQ:NSPH) boosts its rating from a B to an A this week. Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform. Investors have pushed the stock price up 20.4% over the past month. For more information, get Portfolio Grader’s complete analysis of NSPH stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2012/08/8-biotechnology-stocks-to-buy-now-celg-aria-arna/
Short URL: http://investorplace.com/?p=223635
Copyright ©2013 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.